French Healthcare Practitioners Face Five Regulatory Changes Starting September 2026
French healthcare practitioners, including physicians, dentists, and midwives, must comply with five concurrent regulatory changes from September 1, 2026. Among these is a mandate to register on an approved digital platform (Plateforme d'Accueil, or PA) to receive electronic invoices from suppliers. Non-compliance risks a 500€ fine after a formal notice and three-month cure period.
Key takeaways
- French healthcare practitioners must register on an approved digital platform to receive electronic invoices from suppliers starting September 1, 2026.
- Non-registration triggers a formal notice; failure to comply within three months results in a 500€ fine.
- Four concurrent non-e-invoicing changes include sick-leave prescription caps, loss of third-party payment coverage for patients refusing biosimilar or hybrid medication substitutes, and mandatory use of DCI or standard nomenclature for biological medication prescriptions.
- The e-invoicing penalty mechanism is the only change in this cluster with an explicit financial sanction for administrative non-compliance.
- Practitioners must adapt to new prescribing rules, nomenclature obligations, and pharmacy reimbursement restrictions.
Context
The September 1, 2026 deadline marks the first time French healthcare practitioners must register on an approved digital platform to receive electronic invoices from suppliers. This requirement is part of France's broader phased e-invoicing rollout, which has been gradually expanding to various sectors since 2024. The e-invoicing mandate is significant because it represents the first hard compliance deadline specifically affecting healthcare practitioners as invoice recipients, introducing a new administrative burden alongside other regulatory changes.
Beyond e-invoicing, the same decree also imposes three additional obligations: sick-leave prescription caps derived from a June 12, 2026 decree implementing the 2026 Social Security financing law; loss of third-party payment coverage for patients refusing biosimilar or hybrid medication substitutes without medical justification; and mandatory use of International Nonproprietary Names (DCI) or standard nomenclature for biological medication prescriptions, with brand names becoming optional.
What's Changing
The e-invoicing requirement mandates that all medical professionals register on an approved digital platform (PA) to receive electronic invoices from suppliers. Non-registration triggers a formal notice, and failure to comply within three months results in a 500€ fine. This obligation is part of France's broader phased e-invoicing rollout, which has been gradually expanding to various sectors since 2024.
The four concurrent non-e-invoicing changes include:
- Sick-leave prescription caps: Initial prescriptions are limited to 31 days, with renewals capped at 62 days. This change derives from a June 12, 2026 decree implementing the 2026 Social Security financing law.
- Loss of third-party payment coverage: Patients who refuse biosimilar or hybrid medication substitutes without medical justification will lose their entitlement to third-party payment (tiers payant) coverage.
- Mandatory use of DCI or standard nomenclature: Biological medication prescriptions must now use International Nonproprietary Names (DCI) or standard nomenclature. Brand names are optional and no longer mandatory.
Implications for Healthcare Practitioners
The aggregation of these regulatory changes creates a significant administrative and operational burden for healthcare practitioners. The e-invoicing requirement is particularly noteworthy because it introduces a financial penalty for non-compliance, making it a priority tracking item for VAT and e-invoicing policy coverage.
Practitioners must also adapt to new prescribing rules, nomenclature obligations, and pharmacy reimbursement restrictions. The sick-leave prescription caps and loss of third-party payment coverage for patients refusing biosimilar or hybrid medication substitutes will reshape prescribing behavior and patient billing workflows. Additionally, the mandatory use of DCI or standard nomenclature for biological medication prescriptions will require adjustments in prescription practices.
Outlook
The immediate focus for healthcare practitioners should be registering on an approved digital platform to comply with the e-invoicing requirement. The formal notice and three-month cure period before the 500€ fine provide a clear timeline for action.
Looking ahead, practitioners should monitor any updates or clarifications regarding the implementation of these regulatory changes. The aggregation effect of these changes highlights the importance of proactive compliance and adaptation to maintain smooth operations.
Frequently asked questions
- What is the deadline for healthcare practitioners to comply with the e-invoicing requirement?
- Healthcare practitioners must register on an approved digital platform to receive electronic invoices from suppliers starting September 1, 2026.
- What happens if a practitioner does not register on an approved digital platform?
- Non-registration triggers a formal notice; failure to comply within three months results in a 500€ fine.
- What are the sick-leave prescription caps effective September 1, 2026?
- Initial prescriptions are limited to 31 days, with renewals capped at 62 days.
- What happens if a patient refuses biosimilar or hybrid medication substitutes without medical justification?
- Patients who refuse such substitutes without medical justification lose third-party payment (tiers payant) coverage.
- What is the new requirement for biological medication prescriptions?
- Biological medication prescriptions must now use International Nonproprietary Names (DCI) or standard nomenclature. Brand names are optional and no longer mandatory.
